Zum Hauptinhalt springen
Nicht aus der Schweiz? Besuchen Sie lehmanns.de
Advancement in CAR T-Cell Therapy in Tumors -

Advancement in CAR T-Cell Therapy in Tumors

Current Challenges and Future Directions
Buch | Hardcover
332 Seiten
2026
Springer Verlag, Singapore
978-981-95-3627-6 (ISBN)
CHF 299,55 inkl. MwSt
  • Titel nicht im Sortiment
  • Artikel merken
This contributed volume provides a comprehensive overview of CAR T-cell therapy, focusing on its application in solid tumors, an area where treatment success has been more elusive. While CAR T-cell therapy has revolutionized the treatment of hematologic malignancies, its potential in solid tumors remains a frontier of intense research and development. This volume bridges the knowledge gap by addressing both the successes and challenges faced by researchers and clinicians in this evolving field.



The chapters cover topics such as the design of next-generation CAR T-cells, novel targets for solid tumors, and the integration of CAR T-cell therapy with other immunotherapeutic strategies. Readers will discover cutting-edge techniques like CRISPR-mediated gene editing, bispecific CARs, and synthetic biology. The book also explores critical questions about manufacturing challenges, regulatory hurdles, and clinical trial outcomes, providing a holistic view of CAR T-cell therapy. Contributions from leading experts in oncology, immunology, and molecular biology offer a multidisciplinary perspective, making this book a valuable resource for understanding the molecular and clinical dynamics of CAR T-cell therapy.



This book is designed for a diverse audience, including researchers, clinicians, and industry professionals involved in cancer research, immunotherapy, and clinical applications. It is also a key reference for graduate and postgraduate students in fields like oncology, immunology, and biotechnology. By offering a comprehensive analysis of the technical, clinical, and regulatory aspects of CAR T-cell therapy, this book serves as a critical resource in the advancement of cancer treatment.

Dr. Umesh Kumar is currently serving as Associate Director in Chandigarh University, Mohali, Punjab. He has been a Professor and Head, Research Cell in the Department of Biosciences at IMS Ghaziabad (University Courses Campus), Ghaziabad, Uttar Pradesh. He also worked as a Scientific Officer in the Department of Biochemistry at the University of Delhi. His research interests encompass a range of topics, including the molecular diagnosis of cervical cancer, the molecular epigenetics of breast carcinogenesis, CAR T-cell therapy, mesenchymal stem cells, epithelial ovarian carcinoma, and tumor virology.  Dr. Anil Kumar is presently working as Staff Scientist in the National Institute of Immunology, New Delhi. His research interest focuses on understanding the link between gut microbiota and human cancer as well as how the result of the investigation may be helpful to devise strategies to develop gut bacteria/metabolite-based adjuvant immunotherapy for the treatment of colorectal cancer.His research group is also working on exploring the anticancer potential of gut microbiota derived metabolites for cancer treatment. He had participated in the development of biosensors which have been transferred to industry. In 2012, one of his patents has been selected for CSIR Technology Award 2012 and other US patent won Merck Millipore India Innovation Award 2012. Dr. Deepak Parashar is an Assistant Professor in the laboratory of Siegfried Janz in the Division of Hematology and Oncology, Department of Medicine, at the Medical College of Wisconsin (MCW), Milwaukee. His long-term research interests involve the development of a comprehensive understanding of key developmental pathways and how alterations in gene expression contribute to human cancer. His academic training and research experience have provided him with an excellent background in multiple biological disciplines including molecular biology, biochemistry, and genetics. 

Chapter 1: History and Evolution of CAR T-Cell Therapy.- Chapter 2: CAR T-Cell Therapy: Basic Principles and Mechanisms.- Chapter 3: Engineering CAR T-Cells: Advances in Vector Design and Gene Editing.- Chapter 4: Optimizing CAR T-Cell Efficacy: Enhancing Proliferation, Persistence, and Memory.- Chapter 5: Clinical Success of CAR T-Cells in Hematologic Cancers: Lessons from Leukemia and Lymphoma.- Chapter 6: Adverse Effects of CAR T-Cell Therapy and Management: Cytokine Release Syndrome and Neurotoxicity.- Chapter 7: Overcoming Challenges of CAR T-Cell Therapy in Solid Tumor Microenvironments.- Chapter 8: From Bench to Bedside: Innovations and Challenges in CAR-T Cell Therapy Manufacturing and Regulation.- Chapter 9: Combining CAR T Cells with Immunotherapies to Enhance Treatment Effectiveness.- Chapter 10: Next-Generation CARs and Beyond: Synthetic Biology and Logic-Gated in Next-Generation CARs.- Chapter 11: Regulatory landscape and challenges in CAR-T cell therapy development and clinical trials.- Chapter 12: Personalized CAR T-Cell Therapy: Tailoring to Patient-Specific Tumors.

Erscheinungsdatum
Zusatzinfo 27 Illustrations, color; 1 Illustrations, black and white
Verlagsort Singapore
Sprache englisch
Maße 155 x 235 mm
Themenwelt Medizin / Pharmazie Medizinische Fachgebiete Onkologie
Studium Querschnittsbereiche Infektiologie / Immunologie
Schlagworte Cancer Immunotherapy • CAR T-cell therapy • Clinical Translation of Cancer Therapies • Hematologic Malignancies • solid tumors • T-Cell Engineering
ISBN-10 981-95-3627-8 / 9819536278
ISBN-13 978-981-95-3627-6 / 9789819536276
Zustand Neuware
Informationen gemäß Produktsicherheitsverordnung (GPSR)
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich
Infektionen bei Kindern und Jugendlichen
Buch (2025)
Thieme (Verlag)
CHF 209,95